Kraj: Stany Zjednoczone
Język: angielski
Źródło: NLM (National Library of Medicine)
GLYBURIDE (UNII: SX6K58TVWC) (GLYBURIDE - UNII:SX6K58TVWC)
Teva Pharmaceuticals USA, Inc.
GLYBURIDE
GLYBURIDE 1.5 mg
ORAL
PRESCRIPTION DRUG
Glyburide Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glyburide tablets are contraindicated in patients with: - Known hypersensitivity or allergy to the drug. - Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. - Type I diabetes mellitus. - Concomitant administration of bosentan.
Glyburide tablets, USP are supplied as follows: Glyburide Tablets USP 1.5 mg are white, oval-shaped, flat faced, bevel-edged, compressed tablets, debossed with 1.5 | 034 on one side and stylized N on the other side. They are supplied as follows: NDC 0093-8034-01 bottles of 100 Glyburide Tablets USP 3 mg are pale-blue colored, oval-shaped, flat faced, bevel-edged, compressed tablets, debossed with 3 | 035 on one side and stylized N on the other side. They are supplied as follows: NDC 0093-8035-01 bottles of 100 NDC 0093-8035-05 bottles of 500 Glyburide Tablets USP 6 mg are dark-blue colored, oval-shaped, flat faced, bevel-edged, compressed tablets, debossed with 6 | 036 on one side and stylized N on the other side. They are supplied as follows: NDC 0093-8036-01 bottles of 100 Glyburide Tablets USP can be divided in half for a more flexible dosing regimen. Press gently on the score and the tablet will split in even halves. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container with safety closure. Keep container tightly closed. Manufactured In Canada By: Teva Canada Limited Toronto, Canada M1B 2K9 Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. N 1/2023
Abbreviated New Drug Application
GLYBURIDE- GLYBURIDE TABLET TEVA PHARMACEUTICALS USA, INC. ---------- GLYBURIDE TABLETS, USP RX ONLY DESCRIPTION Glyburide tablets, USP contain micronized (smaller particle size) glyburide, USP which is an oral blood-glucose-lowering drug of the sulfonylurea class. Glyburide, USP is a white, crystalline compound. Each tablet, for oral administration, contains 1.5 mg, 3 mg, or 6 mg of glyburide, USP. Inactive ingredients: microcrystalline cellulose, pregelatinized corn starch, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate. In addition, the 3 mg and 6 mg strengths contain FD&C Blue No. 1 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake. The chemical name for glyburide, USP is 1-[[_p_-[2-(5- Chloro-_o_-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohex-ylurea. The structural formula is represented below: C H ClN O S M.W. 494.00 Glyburide Tablets, USP meet USP _Dissolution Test 2._ CLINICAL PHARMACOLOGY ACTIONS Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. 23 28 3 5 Some patients who are initially responsive to oral hypoglycemic drugs, including glyburide, may become unresponsive or poorly responsive over time. Alternatively, glyburide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, glyburide produces Przeczytaj cały dokument